Bringing
immuno-ingenuity™
to life

Inovio is bringing IMMUNO-INGENUITY to life and reshaping the future of treating and preventing cancer and infectious diseases.

Potential HPV Immunotherapy Treatment:

Global Phase III

Clinical Trial - HPV301: Revealing New Treatment Possibilities

Revealing New HPV Treatment Possibilities
Clinical Trial - HPV301

Leading the way in activation immunotherapy

Focusing on treating and preventing cancer and infectious disease

Inovio's technology platform has the potential to be a foundational approach in oncology and infectious disease.

News:

Nov 12, 2019

Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results

Nov 05, 2019

Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)

Oct 29, 2019

Inovio Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019

See all news

Inovio is where
IMMUNO-INGENUITY is making the difference for patients with cancer and infectious diseases.

Learn more about our company

“At Inovio, the revolutionary power of our technology is superseded only by the dedication, passion, and expertise of the team we have brought together to bring our technology to life for patients in need.”

J. Joseph Kim, Ph.D.

President and CEO

Meet our team

Investor information

Review Inovio’s investor presentation highlighting our science, progress, and key upcoming milestones.

Download presentation

Inovio is focusing on transforming the prevention and treatment of cancer and infectious diseases.

Learn more about our focus

Inovio's technology is IMMUNO-INGENUITY in action

Inovio's activation immunotherapy platform is generating best-in-class immune responses in the fight against cancer and infectious diseases.

Explore our technology